Therapeutic Effect of Abelmoschus manihot on Type 2 Diabetic Nonproliferative Retinopathy and the Involvement of VEGF

Table 9

Comparisons of hypoglycemic, hypotensive, and other basic treatment drugs between two groups.

	T group (n = 38)	C group (n = 39)
Hypoglycemic drugs
Metformin	16	17	0.90
Sulfonylureas	16	12	0.30
Glinides	1	0	0.49
Acarbose	18	14	0.31
Thiazolidinedione	3	3	1.00
Insulin	2	0	0.24
Insulin-analog	21	23	0.74
GLP-1	4	6	0.77
DPP-4	12	19	0.13
SGLT-2	3	1	0.59
Hypotensive drugs
CCB	17	11	0.13
βRB	7	9	0.61
ACEI	2	1	0.98
ARB	8	8	0.95
Diuretic	3	4	1.00
Other treatments
Aspirin	7	10	0.45
Statins	13	19	0.20
ARI	1	0	0.49

T: treatment; C: control; CCB: calcium channel blockers; βRB: β receptor blockers; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers; ARI: aldose reductase inhibitor.